MADRIGAL PHARMACEUTICALS, INC. Financial Ratios
MDGL / Health Care|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-47.8%
Profit Margin
-30.1%
Net Income / Revenue
Asset Turnover
0.76
Revenue / Total Assets
Equity Multiplier
2.09
Total Assets / Equity
Composite: -47.8% (reported: -47.8%)
Profitability
Liquidity
Current Ratio
4.01
Quick Ratio
3.77
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.76
Inventory Turnover
-
Days Sales Outstanding
51 days
As of FY2025 · SEC 10-K · Updated Mar 29, 2026
Earnings Quality
Accrual Ratio
-8.6%
-7.6pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.